{"entity":{"id":"lu-177","kind":"isotope","name":"Lutetium-177","aka":["177Lu","Lu-177"],"tldr":"A radioactive metal that gives off short-range radiation. Attached to a molecule that sticks to a tumour, it irradiates the tumour from the inside while sparing most healthy tissue.","summary":"Lutetium-177 is the workhorse therapeutic radionuclide of the theranostic era, carried by DOTATATE (Lutathera, neuroendocrine tumours) and PSMA-617 (Pluvicto, prostate cancer). Its 6.65-day half-life and roughly 0.5-2 mm beta range let it be shipped internationally and deliver a dose that matches small-to-medium tumour deposits.\n\nIts 208 keV gamma emission is imageable, so the same injection that treats the patient can be used for post-therapy SPECT and dosimetry. It can be made carrier-added by direct neutron capture on 176Lu, or no-carrier-added (higher specific activity) via 176Yb(n,γ)177Yb, which decays to 177Lu; the latter avoids the long-lived 177mLu impurity but needs scarce enriched 176Yb.\n\nDemand rose sharply after Pluvicto's 2022 approval, straining the small number of high-flux research reactors (BR2, HFR, Maria, SAFARI-1 and others) and the Russian-dominated supply of enriched ytterbium-176. Shortages in 2022-2023 delayed some Pluvicto doses; new capacity (Bruce Power/Isogen in Canadian CANDU reactors, SHINE's accelerator route) has since expanded supply.","status":"approved","asOf":"2026-09-22","links":[{"label":"Challenges and future options for the production of lutetium-177 (EJNMMI Radiopharm Chem, 2021)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8241800/"},{"label":"FDA label: Pluvicto (lutetium Lu 177 vipivotide tetraxetan)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf"},{"label":"OECD-NEA: Current trends in the supply and utilisation of medical radioisotopes (2025)","url":"https://www.oecd-nea.org/upload/docs/application/pdf/2025-10/7743_medical_radioisotopes_supply_rev.pdf"}],"tags":["therapy","beta emitter"],"related":["pluvicto","lutathera","prrt","lu177-radioligand-therapy","therapy-isotope-supply-chain"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"177Lu","element":"Lutetium","massNumber":177,"halfLife":"6.65 days","emissions":["β− 497 keV maximum (mean 134 keV)","γ 113 keV (6.2%)","γ 208 keV (10.4%)"],"emissionClass":"beta-minus","use":"therapy","tissueRange":"Up to about 2 mm, mean roughly 0.5-0.7 mm","production":"Reactor. Non-carrier-added via 176Yb(n,γ)177Yb, which beta-decays to 177Lu; or carrier-added via direct 176Lu(n,γ)177Lu (co-produces long-lived 177mLu).","supply":"tight","supplyNote":"Demand rose sharply after Pluvicto's approval. Reactor neutron-flux capacity and the scarcity of enriched 176Yb (historically mostly from Russian calutrons) are the binding constraints; new capacity from Bruce Power/Isogen (Canada) and accelerator routes (SHINE) is scaling up.","chelators":["DOTA","DOTAGA"],"pairedWith":["ga-68"],"since":2018},"route":"/isotopes/lu-177/","neighbours":{"drug":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/"},{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/"},{"id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/"},{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/"},{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/"},{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/"},{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/"},{"id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/"},{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/"},{"id":"ga-68-dotatoc","kind":"drug","name":"Gallium-68 edotreotide (DOTATOC)","route":"/drugs/ga-68-dotatoc/"},{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/"},{"id":"iobenguane-i-131","kind":"drug","name":"Iobenguane I-131 (therapeutic)","route":"/drugs/iobenguane-i-131/"},{"id":"locametz","kind":"drug","name":"Locametz (kit for Ga-68 gozetotide)","route":"/drugs/locametz/"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"},{"id":"lu-177-dotatate-generic","kind":"drug","name":"Lutetium-177 dotatate (radioligand equivalent)","route":"/drugs/lu-177-dotatate-generic/"},{"id":"lu-177-pnt2002","kind":"drug","name":"Lutetium-177 PNT2002","route":"/drugs/lu-177-pnt2002/"},{"id":"tlx-591","kind":"drug","name":"Lutetium-177 rosopatamab tetraxetan","route":"/drugs/tlx-591/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"},{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/"}],"technology":[{"id":"albumin-binder-ligands","kind":"technology","name":"Albumin-binder ligands","route":"/technologies/albumin-binder-ligands/"},{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/"},{"id":"automated-synthesis-modules","kind":"technology","name":"Automated synthesis modules","route":"/technologies/automated-synthesis-modules/"},{"id":"caix-pet","kind":"technology","name":"CAIX PET (89Zr-girentuximab)","route":"/technologies/caix-pet/"},{"id":"dota-chelation","kind":"technology","name":"DOTA chelation","route":"/technologies/dota-chelation/"},{"id":"hot-cells-and-shielding","kind":"technology","name":"Hot cells and radiation shielding","route":"/technologies/hot-cells-and-shielding/"},{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/"},{"id":"monte-carlo-dosimetry","kind":"technology","name":"Monte Carlo dosimetry","route":"/technologies/monte-carlo-dosimetry/"},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/"},{"id":"pretargeted-radioimmunotherapy","kind":"technology","name":"Pretargeted radioimmunotherapy","route":"/technologies/pretargeted-radioimmunotherapy/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"quantitative-spect","kind":"technology","name":"Quantitative SPECT","route":"/technologies/quantitative-spect/"},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/"},{"id":"radiohybrid-chemistry","kind":"technology","name":"Radiohybrid (rh) chemistry","route":"/technologies/radiohybrid-chemistry/"},{"id":"radiolabelling-quality-control","kind":"technology","name":"Radiolabelling quality control","route":"/technologies/radiolabelling-quality-control/"},{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"},{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/"},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/"},{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/"},{"id":"spect-dosimetry-workflow","kind":"technology","name":"SPECT dosimetry workflow for radionuclide therapy","route":"/technologies/spect-dosimetry-workflow/"},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/"}],"indication":[{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/"},{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/"},{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/"},{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/"},{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/"},{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/"},{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/"}],"target":[{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/"},{"id":"cck2-receptor","kind":"target","name":"CCK2 receptor (gastrin receptor)","route":"/targets/cck2-receptor/"},{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/"},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/"},{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"},{"id":"sortilin","kind":"target","name":"Sortilin (SORT1)","route":"/targets/sortilin/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"},{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/"},{"id":"ansto","kind":"company","name":"ANSTO (Australian Nuclear Science and Technology Organisation)","route":"/companies/ansto/"},{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/"},{"id":"bracco","kind":"company","name":"Bracco Imaging","route":"/companies/bracco/"},{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/"},{"id":"cellbion","kind":"company","name":"CellBion","route":"/companies/cellbion/"},{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/"},{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/"},{"id":"duchembio","kind":"company","name":"DuChemBio","route":"/companies/duchembio/"},{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","route":"/companies/eckert-ziegler/"},{"id":"full-life-technologies","kind":"company","name":"Full-Life Technologies","route":"/companies/full-life-technologies/"},{"id":"hta-atom-hi-tech","kind":"company","name":"HTA (Atom Hi-Tech)","route":"/companies/hta-atom-hi-tech/"},{"id":"ire","kind":"company","name":"IRE (Institut national des Radioéléments)","route":"/companies/ire/"},{"id":"isotopia","kind":"company","name":"Isotopia Molecular Imaging","route":"/companies/isotopia/"},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/"},{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/"},{"id":"life-molecular-imaging","kind":"company","name":"Life Molecular Imaging","route":"/companies/life-molecular-imaging/"},{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","route":"/companies/mim-software/"},{"id":"molecular-targeting-technologies","kind":"company","name":"Molecular Targeting Technologies","route":"/companies/molecular-targeting-technologies/"},{"id":"niowave","kind":"company","name":"Niowave","route":"/companies/niowave/"},{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","route":"/companies/northstar-medical-radioisotopes/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"},{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","route":"/companies/ntp-radioisotopes/"},{"id":"nuclidium","kind":"company","name":"Nuclidium","route":"/companies/nuclidium/"},{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/"},{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","route":"/companies/shine-technologies/"},{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/"},{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/"},{"id":"trasis","kind":"company","name":"Trasis","route":"/companies/trasis/"},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/"}],"institution":[{"id":"anzup","kind":"institution","name":"ANZUP Cancer Trials Group","route":"/institutions/anzup/"},{"id":"brit","kind":"institution","name":"Board of Radiation and Isotope Technology","route":"/institutions/brit/"},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/"},{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/"},{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","route":"/institutions/irst-meldola/"},{"id":"ksnm","kind":"institution","name":"Korean Society of Nuclear Medicine","route":"/institutions/ksnm/"},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"pathway":[{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/"}],"term":[{"id":"activity-prescription","kind":"term","name":"Activity prescription: fixed versus dosimetry-guided dosing","route":"/terms/activity-prescription/"},{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/"},{"id":"attenuation-correction","kind":"term","name":"Attenuation correction","route":"/terms/attenuation-correction/"},{"id":"authorized-user","kind":"term","name":"Authorized User (AU)","route":"/terms/authorized-user/"},{"id":"becquerel-curie","kind":"term","name":"Becquerel and curie (units of radioactivity)","route":"/terms/becquerel-curie/"},{"id":"biological-half-life","kind":"term","name":"Biological half-life","route":"/terms/biological-half-life/"},{"id":"chelator-term","kind":"term","name":"Chelator (bifunctional chelating agent)","route":"/terms/chelator-term/"},{"id":"crossover","kind":"term","name":"Crossover in trials","route":"/terms/crossover/"},{"id":"cytopenias","kind":"term","name":"Cytopenias and myelosuppression","route":"/terms/cytopenias/"},{"id":"effective-half-life","kind":"term","name":"Effective half-life","route":"/terms/effective-half-life/"},{"id":"fixed-versus-personalised-dosing","kind":"term","name":"Fixed versus personalised (dosimetry-guided) dosing","route":"/terms/fixed-versus-personalised-dosing/"},{"id":"gray-unit","kind":"term","name":"Gray unit (Gy)","route":"/terms/gray-unit/"},{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/"},{"id":"krenning-score","kind":"term","name":"Krenning score","route":"/terms/krenning-score/"},{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/"},{"id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/"},{"id":"myelosuppression-after-rlt","kind":"term","name":"Myelosuppression after radioligand therapy","route":"/terms/myelosuppression-after-rlt/"},{"id":"no-carrier-added","kind":"term","name":"No-carrier-added (n.c.a.) and carrier-added production","route":"/terms/no-carrier-added/"},{"id":"partial-volume-effect","kind":"term","name":"Partial volume effect (PVE)","route":"/terms/partial-volume-effect/"},{"id":"patient-release-criteria","kind":"term","name":"Patient release criteria after radioactive treatment","route":"/terms/patient-release-criteria/"},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/"},{"id":"psma-rads","kind":"term","name":"PSMA-RADS (PSMA reporting and data system)","route":"/terms/psma-rads/"},{"id":"radiochemical-purity","kind":"term","name":"Radiochemical purity (RCP)","route":"/terms/radiochemical-purity/"},{"id":"radiolysis","kind":"term","name":"Radiolysis (self-radiolysis of radiopharmaceuticals)","route":"/terms/radiolysis/"},{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/"},{"id":"renal-protection-amino-acids","kind":"term","name":"Renal protection with amino acid co-infusion","route":"/terms/renal-protection-amino-acids/"},{"id":"salivary-gland-toxicity","kind":"term","name":"Salivary gland toxicity (xerostomia) from PSMA radioligand therapy","route":"/terms/salivary-gland-toxicity/"},{"id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/"},{"id":"theranostic-pair-term","kind":"term","name":"Theranostic pair","route":"/terms/theranostic-pair-term/"},{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/"},{"id":"time-activity-curve","kind":"term","name":"Time-activity curve (TAC)","route":"/terms/time-activity-curve/"}],"trial":[{"id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/"},{"id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/"},{"id":"nct06184035","kind":"trial","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","route":"/trials/nct06184035/"},{"id":"nct05547061","kind":"trial","name":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","route":"/trials/nct05547061/"},{"id":"nct06383052","kind":"trial","name":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","route":"/trials/nct06383052/"},{"id":"nct06247995","kind":"trial","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","route":"/trials/nct06247995/"},{"id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/"},{"id":"nct05459844","kind":"trial","name":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","route":"/trials/nct05459844/"},{"id":"nct05658003","kind":"trial","name":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","route":"/trials/nct05658003/"},{"id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/"},{"id":"nct04939610","kind":"trial","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","route":"/trials/nct04939610/"},{"id":"nct07047118","kind":"trial","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct07047118/"},{"id":"nct05706129","kind":"trial","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05706129/"},{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/"},{"id":"nct05884255","kind":"trial","name":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","route":"/trials/nct05884255/"},{"id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/"},{"id":"nct06894511","kind":"trial","name":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","route":"/trials/nct06894511/"},{"id":"nct05413850","kind":"trial","name":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","route":"/trials/nct05413850/"},{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/"},{"id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/"},{"id":"enza-p","kind":"trial","name":"ENZA-p","route":"/trials/enza-p/"},{"id":"nct07357519","kind":"trial","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","route":"/trials/nct07357519/"},{"id":"lutectomy","kind":"trial","name":"LuTectomy","route":"/trials/lutectomy/"},{"id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/"},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/"},{"id":"nct05682443","kind":"trial","name":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","route":"/trials/nct05682443/"},{"id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/"},{"id":"nct06139575","kind":"trial","name":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","route":"/trials/nct06139575/"},{"id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/"},{"id":"prince-trial","kind":"trial","name":"PRINCE","route":"/trials/prince-trial/"},{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/"},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/"},{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/"},{"id":"nct06004661","kind":"trial","name":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","route":"/trials/nct06004661/"},{"id":"nct04711135","kind":"trial","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","route":"/trials/nct04711135/"},{"id":"nct06784752","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","route":"/trials/nct06784752/"},{"id":"nct03972488","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","route":"/trials/nct03972488/"},{"id":"nct06520345","kind":"trial","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","route":"/trials/nct06520345/"},{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/"},{"id":"upfront-psma","kind":"trial","name":"UpFrontPSMA","route":"/trials/upfront-psma/"},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/"}],"pairing":[{"id":"pluvicto-plus-olaparib","kind":"pairing","name":"177Lu-PSMA-617 (Pluvicto) with olaparib","route":"/pairings/pluvicto-plus-olaparib/"},{"id":"beta-psma-then-alpha-psma-rescue","kind":"pairing","name":"177Lu-PSMA-617 then 225Ac-PSMA rescue therapy","route":"/pairings/beta-psma-then-alpha-psma-rescue/"},{"id":"ga68-dotatate-then-lutathera","kind":"pairing","name":"68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)","route":"/pairings/ga68-dotatate-then-lutathera/"},{"id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/"},{"id":"beta-then-alpha","kind":"pairing","name":"Beta radioligand → alpha radioligand","route":"/pairings/beta-then-alpha/"},{"id":"docetaxel-then-lu177-psma","kind":"pairing","name":"Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617","route":"/pairings/docetaxel-then-lu177-psma/"},{"id":"prrt-plus-captem","kind":"pairing","name":"PRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)","route":"/pairings/prrt-plus-captem/"},{"id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/"},{"id":"sstr-pet-to-prrt","kind":"pairing","name":"SSTR PET → PRRT","route":"/pairings/sstr-pet-to-prrt/"}],"idea":[{"id":"idea-reg-medical-isotope-reactor-reserve","kind":"idea","name":"A coordinated reserve and shared schedule for the world's medical isotope reactors","route":"/ideas/idea-reg-medical-isotope-reactor-reserve/"},{"id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","route":"/ideas/idea-reg-isotope-supply-observatory/"},{"id":"idea-copper-theranostic-pair-standard","kind":"idea","name":"A single-molecule copper-64/copper-67 pair instead of switching ligands between scan and treatment","route":"/ideas/idea-copper-theranostic-pair-standard/"},{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/"},{"id":"idea-rlt-plus-checkpoint-inhibitor","kind":"idea","name":"Adding a checkpoint inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-checkpoint-inhibitor/"},{"id":"idea-rlt-plus-parp-inhibitor","kind":"idea","name":"Adding a PARP inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-parp-inhibitor/"},{"id":"idea-ai-lesion-segmentation-dosimetry","kind":"idea","name":"AI segmentation to make voxel-level radioligand dosimetry practical at scale","route":"/ideas/idea-ai-lesion-segmentation-dosimetry/"},{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/"},{"id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/"},{"id":"idea-alpha-for-oligometastatic-disease","kind":"idea","name":"Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer","route":"/ideas/idea-alpha-for-oligometastatic-disease/"},{"id":"idea-bispecific-radioligands","kind":"idea","name":"Bispecific PSMA/GRPR radioligands for discordant prostate cancer lesions","route":"/ideas/idea-bispecific-radioligands/"},{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/"},{"id":"idea-caix-theranostics","kind":"idea","name":"CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy","route":"/ideas/idea-caix-theranostics/"},{"id":"idea-net-dosimetry-prrt","kind":"idea","name":"Dosimetry-personalised PRRT instead of four fixed cycles","route":"/ideas/idea-net-dosimetry-prrt/"},{"id":"idea-fap-theranostics-sarcoma","kind":"idea","name":"FAP-targeted radioligand therapy for sarcoma","route":"/ideas/idea-fap-theranostics-sarcoma/"},{"id":"idea-regional-radiopharmacy-network","kind":"idea","name":"In-house hospital radiopharmacy compounding to cut dose waste","route":"/ideas/idea-regional-radiopharmacy-network/"},{"id":"idea-dosimetry-guided-dosing-standard","kind":"idea","name":"Kidney-dosimetry-guided dosing as the default for PSMA radioligand therapy","route":"/ideas/idea-dosimetry-guided-dosing-standard/"},{"id":"idea-neoadjuvant-psma-therapy","kind":"idea","name":"Neoadjuvant PSMA radioligand therapy before prostatectomy","route":"/ideas/idea-neoadjuvant-psma-therapy/"},{"id":"idea-pretargeted-alpha-therapy","kind":"idea","name":"Pretargeted alpha radioimmunotherapy","route":"/ideas/idea-pretargeted-alpha-therapy/"},{"id":"idea-net-antagonist-ligands","kind":"idea","name":"SSTR antagonist radioligands to increase tumour dose","route":"/ideas/idea-net-antagonist-ligands/"},{"id":"idea-tb161-instead-of-lu177","kind":"idea","name":"Terbium-161 instead of lutetium-177 in the same ligands","route":"/ideas/idea-tb161-instead-of-lu177/"},{"id":"idea-total-body-pet-dosimetry","kind":"idea","name":"Total-body PET for personalised radioligand dosing","route":"/ideas/idea-total-body-pet-dosimetry/"}],"person":[{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/"},{"id":"amir-iravani","kind":"person","name":"Amir Iravani","route":"/people/amir-iravani/"},{"id":"dale-bailey","kind":"person","name":"Dale L. Bailey","route":"/people/dale-bailey/"},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/"},{"id":"erik-mittra","kind":"person","name":"Erik S. Mittra","route":"/people/erik-mittra/"},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/"},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/"},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/"},{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/"},{"id":"lisa-bodei","kind":"person","name":"Lisa Bodei","route":"/people/lisa-bodei/"},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/"},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/"},{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","route":"/people/michael-lassmann/"},{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/"},{"id":"phillip-kuo","kind":"person","name":"Phillip H. Kuo","route":"/people/phillip-kuo/"},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/"},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/"},{"id":"rodney-hicks","kind":"person","name":"Rodney J. Hicks","route":"/people/rodney-hicks/"},{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","route":"/people/scott-tagawa/"},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/"},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/"},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/"},{"id":"wolfgang-fendler","kind":"person","name":"Wolfgang P. Fendler","route":"/people/wolfgang-fendler/"}],"bottleneck":[{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/"},{"id":"b-rlt-trial-capacity","kind":"bottleneck","name":"Clinical trial capacity for radioligand therapy","route":"/bottlenecks/b-rlt-trial-capacity/"},{"id":"b-dosimetry-standardisation","kind":"bottleneck","name":"Dosimetry standardisation for radioligand therapy","route":"/bottlenecks/b-dosimetry-standardisation/"},{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/"},{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/"},{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/"}],"paper":[{"id":"paper-kratochwil-ac225-psma-jnm-2016","kind":"paper","name":"225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer","route":"/key-papers/paper-kratochwil-ac225-psma-jnm-2016/"},{"id":"paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022","kind":"paper","name":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","route":"/key-papers/paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022/"},{"id":"paper-strosberg-netter1-qol-jco-2018","kind":"paper","name":"Health-related quality of life in the NETTER-1 trial of 177Lu-Dotatate","route":"/key-papers/paper-strosberg-netter1-qol-jco-2018/"},{"id":"paper-hofman-lupsma-lancet-oncol-2018","kind":"paper","name":"LuPSMA trial: single-arm phase 2 study of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-hofman-lupsma-lancet-oncol-2018/"},{"id":"paper-netter-1-nejm-2017","kind":"paper","name":"NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide","route":"/key-papers/paper-netter-1-nejm-2017/"},{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/"},{"id":"paper-tagawa-ac225-j591-jco-2024","kind":"paper","name":"Phase I dose-escalation study of 225Ac-J591, a PSMA-targeting alpha-emitting antibody, in mCRPC","route":"/key-papers/paper-tagawa-ac225-j591-jco-2024/"},{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC","route":"/key-papers/paper-psmafore-lancet-2024/"},{"id":"paper-sgouros-tat-review-nat-rev-2020","kind":"paper","name":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","route":"/key-papers/paper-sgouros-tat-review-nat-rev-2020/"},{"id":"paper-herrmann-radiotheranostics-lancet-oncol-2020","kind":"paper","name":"Radiotheranostics: a roadmap for future development","route":"/key-papers/paper-herrmann-radiotheranostics-lancet-oncol-2020/"},{"id":"paper-baum-prrt-1048-patients-oncotarget-2018","kind":"paper","name":"Results and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms","route":"/key-papers/paper-baum-prrt-1048-patients-oncotarget-2018/"},{"id":"paper-therap-lancet-2021","kind":"paper","name":"TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-therap-lancet-2021/"},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/"}],"journal":[{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/"},{"id":"nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Nuclear Medicine and Molecular Imaging","route":"/journals/nuclear-medicine-and-molecular-imaging/"}],"opportunity":[{"id":"opp-dll3-imaging-sclc","kind":"opportunity","name":"DLL3 imaging for small-cell lung cancer","route":"/opportunities/opp-dll3-imaging-sclc/"},{"id":"opp-fap-pancreatic-staging","kind":"opportunity","name":"FAP imaging to stop futile pancreatic surgery","route":"/opportunities/opp-fap-pancreatic-staging/"},{"id":"opp-grpr-psma-negative-prostate","kind":"opportunity","name":"GRPR imaging when the PSMA scan is negative","route":"/opportunities/opp-grpr-psma-negative-prostate/"}],"collection":[{"id":"opendose","kind":"collection","name":"OpenDose","route":"/collections/opendose/"},{"id":"snmmi-procedure-standards","kind":"collection","name":"SNMMI Procedure Standards","route":"/collections/snmmi-procedure-standards/"},{"id":"nrc-regulations-part35","kind":"collection","name":"US NRC 10 CFR Part 35 (Medical Use of Byproduct Material)","route":"/collections/nrc-regulations-part35/"}],"section":[{"id":"f-dosimetry","kind":"section","name":"Dosimetry","route":"/fronts/f-dosimetry/"},{"id":"f-isotope-supply","kind":"section","name":"Isotope supply","route":"/fronts/f-isotope-supply/"},{"id":"f-radiochemistry","kind":"section","name":"Radiochemistry & manufacturing","route":"/fronts/f-radiochemistry/"},{"id":"f-radioligand-therapy","kind":"section","name":"Radioligand therapy","route":"/fronts/f-radioligand-therapy/"},{"id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/"}],"isotope":[{"id":"sc-47","kind":"isotope","name":"Scandium-47","route":"/isotopes/sc-47/"},{"id":"tb-161","kind":"isotope","name":"Terbium-161","route":"/isotopes/tb-161/"}],"roadmap":[{"id":"alpha-therapy-roadmap","kind":"roadmap","name":"Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline","route":"/roadmaps/alpha-therapy-roadmap/"},{"id":"dosimetry-roadmap","kind":"roadmap","name":"Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose","route":"/roadmaps/dosimetry-roadmap/"},{"id":"isotope-supply-roadmap","kind":"roadmap","name":"Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium","route":"/roadmaps/isotope-supply-roadmap/"},{"id":"psma-theranostics-roadmap","kind":"roadmap","name":"PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha","route":"/roadmaps/psma-theranostics-roadmap/"},{"id":"sstr-theranostics-roadmap","kind":"roadmap","name":"SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha","route":"/roadmaps/sstr-theranostics-roadmap/"}]}}